FINWIRES · TerminalLIVE
FINWIRES

$GSK

57 stories mentioning GSKUpdated 5d ago

Every FINWIRES story that references GSK, newest first.

What's the latest news on GSK?

Sectors

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Tuesday

Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.2%.GSK (GSK) shares were up more than 2% after the company posted higher Q2 core earnings and sales.IQVIA (IQV) stock was up more than 11% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Centene (CNC) shares were down more than 5% even after the company reported that it swung to Q2 adjusted earnings as revenue increased during the period. Centene also lifted its 2026 guidance.

$CNC$GSK$IBB$IQV$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to higher pre-bell Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 1.3%.GSK (GSK) shares were up more than 1% after the company posted higher Q2 core earnings and sales.

$GSK
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.5%.The iShares Biotechnology ETF (IBB) fell 0.9%.In corporate news, Repligen (RGEN) has agreed to acquire BioLife Solutions (BLFS) in a deal valued at about $1.5 billion, the companies said. Repligen shares climbed 2.3%, and BioLife jumped past 6%.Amgen (AMGN) has agreed to pay $74 million to settle a shareholder lawsuit alleging the company waited too long to disclose it may owe the Internal Revenue Service $10.7 billion in back taxes, penalties and interest, news outlets reported Tuesday. Amgen shares were down 0.1%.Arrowhead Pharmaceuticals (ARWR) shares surged past 20% after the company said its phase 3 clinical studies of plozasiran to treat hypertriglyceridemia met the primary endpoint of triglyceride reduction compared with placebo.GSK (GSK) shares were fractionally higher after it said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.

$AMGN$ARWR$BLFS$GSK$RGEN
Wire

GSK Gets FDA Approval for Jideytro in Previously Treated ROS1-Positive Lung Cancer

GSK (GSK) said Wednesday the US Food and Drug Administration has approved Jideytro, a ROS1-selective inhibitor, to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor.The approval, based on the phase I/II Arros-1 trial, comes ahead of the original Sept. 18 target action date after the FDA granted Jideytro Breakthrough Therapy and Orphan Drug designations.The therapy aims to combine high target-selectivity, broad coverage of ROS1 resistance mutations, and blood-brain barrier penetration to address disease in the brain, the company added.Jideytro is GSK's first approved medicine in lung cancer.Price: $50.93, Change: $+0.15, Percent Change: +0.30%

$GSK
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said in a note. Lilly shares were up 0.7%.Intuitive Surgical (ISRG) shares fell nearly 14%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.1% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Xencor (XNCR) shares jumped about 13% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$GSK$ISRG$LLY$XNCR
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Friday afternoon, with the NYSE Healthcare Index increasing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Intuitive Surgical (ISRG) shares fell past 12%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.7% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Takeda Pharmaceutical (TAK) shares rose 2%. The company said late Thursday that new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$ISRG$TAK
Asia Markets

European Equities Traded in the US as American Depositary Receipts Decline Friday

European equities traded in the US as American depositary receipts were lower on Friday morning, shedding 0.6% to 1,899.52 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by energy companies Equinor (EQNR) and Eni (E), which climbed 4.1% and 3.1% respectively.They were followed by biotech companies Genenta Science (GNTA) and DBV Technologies (DBVT), which added 3% and 2.2%.The decliners from continental Europe were led by tech company Nokia (NOK), which dropped 3%, and semiconductor companies STMicroelectronics (STM) and ASML (ASML), which fell 2.6% each.They were followed by software company SAP (SAP), which shed 1.8%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways (CMPS), which climbed 4.8%, and energy companies Shell (SHEL) and BP (BP), which added 2.3% and 1.4% respectively.The decliners from the UK and Ireland were led by budget airline Ryanair (RYAAY) and pharmaceutical company GSK (GSK), which lost 3.6% and 2.8% respectively. They were followed by bank Barclays (BCS), which shed 2.1%.

$ASML$BCS$BP$CMPS$DBVT$E$EQNR$GNTA$GSK$NOK$RYAAY$SAP$SHEL$STM
Sectors

Sector Update: Healthcare Stocks Mixed Premarket Friday

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) 0.7% lower.GSK (GSK) shares were down more than 3% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Novartis (NVS) shares were up more than 1% after the company said the US Food and Drug Administration approved Fabhalta under the traditional approval pathway to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression.Takeda Pharmaceutical (TAK) shares were 0.6% higher after the company said new phase 3 data showed its oral TYK2 inhibitor, zasocitinib, delivered high rates of skin clearance across difficult-to-treat body sites in adults with moderate-to-severe plaque psoriasis.

$GSK$IBB$NVS$TAK$XLV
Commodities

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.7%, and the actively traded Invesco QQQ Trust (QQQ) fell 1.8% in Friday's premarket activity, as investors continued to pull back from chipmakers.US stock futures were also lower, with S&P 500 Index futures down 0.8%, Dow Jones Industrial Average futures slipping 0.5%, and Nasdaq futures declining 1.6% before the start of regular trading.June housing starts jumped by 19% from the previous month to a 1.427 million annual rate, above expectations compiled by Bloomberg as of 7:30 am ET for a 1.310 million rate after a decrease to a 1.199 million pace in May.US import prices rose by 0.3% in June, compared to the 0.7% decrease expected in a survey compiled by Bloomberg and following a 1.7% increase in May.Industrial production data for June will be released at 9:15 am ET, followed by the preliminary University of Michigan consumer sentiment reading for July at 10:00 am ET.In premarket action, bitcoin was down by 1.5%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.7% lower, Ether ETF (EETH) retreated 2%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 1.3%.Power Play:ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.6%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) was up 0.7%, and the iShares US Consumer Staples ETF (IYK) advanced 0.9%. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.7%. The VanEck Retail ETF (RTH) gained 1%, while the State Street SPDR S&P Retail ETF (XRT) was 0.5% lower.XPeng (XPEV) shares were down more than 5% pre-bell after closing the prior session with a 1% rise. The Wall Street Journal reported Thursday that the company is launching its L03 SUV in Munich, marking its first global vehicle launch outside China as it expands in Europe and other overseas markets.Winners and Losers:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) retreated 2.2%, and the iShares US Technology ETF (IYW) was 2.1% lower, while the iShares Expanded Tech Sector ETF (IGM) was down 2.1%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) declined 3.4%, while the iShares Semiconductor ETF (SOXX) fell by 3.9%.Cadence Design Systems (CDNS) shares were down more than 5% in premarket activity following a 1.8% fall at the prior close. The company said it will work with logic semiconductor manufacturer Rapidus to advance "agentic AI" for advanced-node system-on-chip design under a new collaboration.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated 0.6%, while the Vanguard Industrials Index Fund (VIS) and the iShares US Industrials ETF (IYJ) were flat.SpaceX's (SPCX) stock was down more than 4% before the opening bell after CEO Elon Musk said in a Thursday post on X that the company's Starship rocket triggered an "automatic launch abort," with the next launch to be rescheduled possibly "in a few days".Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.4%, the Vanguard Health Care Index Fund (VHT) was up 0.1%, while the iShares US Healthcare ETF (IYH) slipped 0.5%. The iShares Biotechnology ETF (IBB) was down 0.4%.GSK (GSK) stock was down more than 2% premarket after the company said it would discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.EnergyThe iShares US Energy ETF (IYE) was up 0.6%, while the State Street Energy Select Sector SPDR ETF (XLE) was 1.5% higher.BP (BP) stock was up more than 1%, and ConocoPhillips (COP) was 2% higher before market open. CNBC reported Friday that the companies plan to reveal billions of dollars in new investments in Iraq to help build its energy sector and increase resilience against Iranian disruptions.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) advanced 0.1%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.2%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.1% lower.Truist Financial (TFC) shares traded down 1% in early hours activity, even after the company reported higher Q2 earnings and revenue.CommoditiesFront-month US West Texas Intermediate crude oil advanced by 2.7% to $81.04 per barrel on the New York Mercantile Exchange. Natural gas was up by 0.5% to $2.87 per 1 million British Thermal Units. The United States Oil Fund (USO) was up 2.4%, while the United States Natural Gas Fund (UNG) was 1% lower.Gold futures for July retreated 0.1% to $3,988.00 an ounce on the Comex. Silver futures were down 1.1% to $55.59 an ounce. SPDR Gold Shares (GLD) decreased 0.2%, and the iShares Silver Trust (SLV) was 0.9% lower.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$BP$CDNS$COP$EEM$EETH$EXI$FAS$FAZ$GLD$GSK$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$TFC$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XPEV$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.6% lower.GSK (GSK) shares were down more than 2% after the company said it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.

$GSK
Wire

GSK Licensor Hansoh Reports Positive Phase 3 Results for Risvutatug Rezetecan in China

GSK (GSK) said Friday its licensor, Hansoh Pharmaceutical, reported the phase 3 Artemis-008 trial of risvutatug rezetecan met its primary overall survival endpoint in Chinese patients with advanced or relapsed small-cell lung cancer.The study showed statistically significant and clinically meaningful improvements in overall survival versus topotecan, with benefits also observed across key secondary endpoints, including progression-free survival.The results mark the first positive phase 3 overall survival data for a B7-H3-targeted antibody-drug conjugate in any tumor type and support the continued global development of Ris-Rez outside Greater China, GSK said.GSK shares were up 1% in Friday premarket trading.

$GSK
Sectors

Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday

Healthcare stocks were leaning lower premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) declining by 0.6%.Astrazeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to certain patients, Bloomberg reported, citing people familiar with the negotiations. Shares of Astrazeneca were down more than 1% pre-bell.GSK (GSK) agreed to expand its exclusive strategic collaboration with Sino Biopharmaceutical's Chia Tai Tianqing Pharmaceutical Group subsidiary to include rights to commercialize two GSK respiratory therapies in mainland China, Sino said in a filing. GSK stock was down more than 1% premarket.Seres Therapeutics (MCRB) shares were up more than 2% after the company said top-line results from a phase 1 clinical trial of SER-155 to treat patients with immune checkpoint inhibitor-related enterocolitis met its primary endpoint.

$AZN$GSK$IBB$MCRB$XLV
Wire

GSK Unit Launches Tender Offer for Nuvalent Acquisition

GSK (GSK) said Wednesday its Harmony Row Acquisition unit commenced a tender offer to purchase all outstanding Class A and Class B shares of Nuvalent (NUVL) for $124 per share in cash.Following the consummation of the offer, the unit will merge into Nuvalent, which will continue as a direct wholly-owned subsidiary of GlaxoSmithKline LLC.Nuvalent's board of directors recommended that stockholders accept the offer and tender their shares, GSK said.The tender offer and withdrawal rights will expire on July 14, the company added.Price: $51.20, Change: $-0.87, Percent Change: -1.67%

$GSK$NUVL
Wire

GSK, Spero Therapeutics Get FDA Approval for Utebzi in Complicated Urinary Tract Infections

GSK (GSK) and Spero Therapeutics (SPRO) said Wednesday that the US Food and Drug Administration has approved Utebzi as treatment for complicated urinary tract infections, including pyelonephritis, in adults.Utebzi, or tebipenem pivoxil, is the first and only oral carbapenem antibiotic approved in the US and is expected to become available by the end of 2026, the companies said.The approval was based on phase 3 trial data showing Utebzi's non-inferiority to intravenous imipenem-cilastatin, with tebipenem pivoxil achieving an overall success rate of 58.5% against 60.2% for imipenem-cilastatin, according to a statement. Tebipenem pivoxil's safety profile is also "generally similar" to that of imipenem-cilastatin, the companies said.GSK shares were up about 1%, while Spero stock was down more than 14% in Wednesday trading.Price: $52.72, Change: $+0.50, Percent Change: +0.96%

$GSK$SPRO
Sectors

Sector Update: Healthcare Stocks Ease Late Afternoon

Healthcare stocks eased late Tuesday afternoon with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.The iShares Biotechnology ETF (IBB) also dropped 0.2%.In corporate news, Eli Lilly (LLY) acquired 4E Therapeutics, a neuroscience firm creating chronic-pain treatments. Lilly shares fell 1%.CAMP4 Therapeutics (CAMP) shares jumped 6.1% after JPMorgan upgraded the stock to overweight from neutral and raised its price target to $9 from $5.GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares eased 0.1%.Oncolytics Biotech (ONCY) shares climbed 11% after the company received a US patent covering the pelareorep manufacturing process into 2044.

$CAMP$GSK$LLY$ONCY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks edged higher Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 0.2%.The iShares Biotechnology ETF (IBB) was down 0.2%.In corporate news, GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation. GSK shares rose 0.3%.Novo Nordisk (NVO) plans to apply for Chinese regulatory approval of its oral weight-loss drug, Wegovy, within the next few months, Reuters reported, citing Chief Executive Mike Doustdar. According to the report, Eli Lilly (LLY) submitted a marketing application in China for its oral obesity drug late last year, putting the company ahead of Novo in the race to launch a weight-loss pill in the country. Novo shares were down 0.3%, and Lilly was 0.1% lower.Oncolytics Biotech (ONCY) shares jumped past 10% after it said Tuesday it has received a US patent covering the pelareorep manufacturing process into 2044.

$GSK$LLY$NVO$ONCY
Wire

GSK's Exdensur Wins Canadian Approval for Severe Asthma, Nasal Polyps

GSK (GSK) said Health Canada approved Exdensur for severe eosinophilic asthma, which is driven by elevated white blood cells, and for chronic rhinosinusitis with nasal polyps, a condition that causes blockage and inflammation.Exdensur is the first long-acting biologic in Canada to offer twice-yearly dosing for these conditions, GSK said Tuesday in a statement.The approval was supported by late-stage trials showing the drug significantly reduced asthma exacerbations, including those requiring hospitalization or emergency care, and reduced nasal polyp size and obstruction versus placebo.Price: $52.45, Change: $+0.22, Percent Change: +0.42%

$GSK
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 1.6% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) added 1.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 1%, and Nuvalent surged 39%.Brookdale Senior Living (BKD) has reported May occupancy data in line with bullish comments by the company's management at a recent event and ahead of levels implied in RBC's model for Q2, RBC Capital Markets said in a note. Brookdale shares jumped past 8%.PTC Therapeutics (PTCT) shares climbed 3.3% after Citigroup upgraded the company's stock to buy and raised its price target to $108.Eli Lilly (LLY) signed a collaboration and licensing deal worth over $1 billion with AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.4%.

$BKD$GSK$LLY$NUVL$PTCT
Wire

Nuvalent Acquisition Fairly Valued, Competing Bid Seen as Unlikely, Wedbush Says

Nuvalent (NUVL) is fairly valued following GSK's (GSK) agreed acquisition of the company, with limited likelihood of a competing bid emerging, Wedbush Securities said in a Tuesday note.The brokerage said most logical strategic acquirers, including Pfizer (PFE), Roche and Bristol Myers Squibb (BMY), already have meaningful exposure to ALK- and ROS1-positive non-small cell lung cancer markets, making it difficult to justify a higher offer while achieving attractive returns.Wedbush said the deal validates the value of differentiated precision oncology assets with advantages in efficacy, tolerability, resistance mutation coverage and CNS penetration.The investment firm downgraded Nuvalent to neutral from outperform and lowered its price target to $124 from $125, matching the agreed tender offer price from GSK.Shares of Nuvalent rose more than 39% in Tuesday afternoon trading.Price: $123.12, Change: $+34.63, Percent Change: +39.13%

$GSK$NUVL
Sectors

Sector Update: Healthcare Stocks Rise Tuesday Afternoon

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.8%.The iShares Biotechnology ETF (IBB) rose 0.2%.In corporate news, GSK (GSK) said it signed a definitive agreement Tuesday to acquire Nuvalent (NUVL) for $10.6 billion in cash. GSK shares rose 0.9%, and Nuvalent surged 39%.Eli Lilly (LLY) entered into a collaboration and licensing agreement worth over $1 billion with Swedish pharmaceutical company AlzeCure Pharma for global rights to its investigative candidate for Alzheimer's disease. Lilly shares were down 0.5%.NeuroSense Therapeutics (NRSN) shares added 1% after it said Tuesday that it has been issued a patent by the Japan Patent Office for PrimeC, its lead drug candidate to treat amyotrophic lateral sclerosis.

$GSK$LLY$NRSN$NUVL

Showing 21-40 of 57

Track with the FINWIRES app suite

FolioX
FolioX
Track GSK in your portfolio
WheelAI
WheelAI
Analyze GSK options with the wheel strategy
StockInsider
StockInsider
See market sentiment on GSK